IMCLONE GOES UP AGAINST PATENT DISPUTE

More bad news could be looming for ImClone Systems, the biotech maker at the heart of the Martha Stewart stock scandal. A federal judge is expected to rule, possibly within weeks, on a bitter patent dispute affecting ImClone's sole product, cancer drug Erbitux.

USA Today (http://www.usatoday.com/money/industries/health/drugs/2006-09-14-imclone-usat_x.htm?csp=N008)